Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

Genmab, de Deense parel

3.464 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 170 171 172 173 174 » | Laatste

Omlaag ↓

poolbeer 6 juni 2013 20:33

J&J nam ook een 10% belang in Crucell voordat ze het helemaal overnamen. Zouden ze hetzelfde kunstje weer flikken?

sheriff Grover 6 juni 2013 20:40

Ik persoonlijk denk dat als er al een partij een bod doet het eerder GSK zal zijn (die hebben al zoveel geld in die arzerra ontwikkeling zitten dat ze nooit de vruchten door een ander zullen willen laten plukken ) maar wie weet komt er wel een gezamenlijk bod GSK arzerra en J&J de rest of zoiets dergelijks . Het punt is als er serieus geld verdient gaat worden dat ze wel zullen moeten het wordt te duur om Genmab dan niet over te nemen ..

poolbeer 6 juni 2013 21:05

Afwachten maar Genmab zit een luxe positie. Overigens was het geen 10% maar 18% belang (in sept. 2009)en na een jaar heeft J&J Crucell overgenomen. De J&J deal met Genmab was aug. 2012. Ben benieuwd.

sheriff Grover 14 juni 2013 13:59

Laurens Schotman ....

We maken ons wel eens druk over de koers van ons aandeel of over nieuws wat uitblijft of niet snel genoeg komt maar als puntje bij paaltje komt gaat het maar over 1 ding , laat het medicijn alsjeblieft mensen helpen of nog beter genezen ....

een naar mijn mening indrukwekkend blog van een patient

laurensschotman.blogspot.nl/

Sheriff Grover

sloebervos 16 juni 2013 09:58

Beste allemaal,kan iemand mij zeggen wat er zal gebeuren met de aandelen van GENMAB die genoteerd waren op de duitse beurs onder de ticker GE9.
Die staan op mijn beursrekening bij Keytrade nog altijd genoteerd op de koers van 9/11/2011 aan de koers van 3,96€.Vrijdag op de deense beurs was dat 184,5DK(ca24,7€).Ik heb inlichtingen genomen bij de bank en daar zeggen ze dat ik ze kan laten omwisselen maar dat er wel "kosten" zullen aangerekend worden maar ze kunnen niet zeggen hoeveel.Afwachten?Wat gebeurt er ingeval van overname met die aandelen?Worden ze automatisch ook overgenomen?Daar het maar over 200 aandelen gaat ben ik bang dat de kosten wel eens procentueel hoog zouden zijn.Is er iemand die in dezelfde situatie geweest is en mij kan vertellen hoe hij het heeft opgelost.In alle geval,bedankt voor alle inlichtingen.

sheriff Grover 17 juni 2013 17:05

Hallo Sloebervos ik zou het eerlijk gezegd niet weten maar heb je die kosten al eens nagevraagd ?? lijkt me dat ze je dat toch wel moeten kunnen melden ?? En anders heb je ze al eens geprobeerd te verhandelen misschien als je ze aanbied je wel de juiste koers krijgt ??

sloebervos 17 juni 2013 20:13

Bedankt sheriff,ik zal de evolutie van het aandeel nog eventjes volgen en als ze verder blijven stijgen zal ik de bank concreet de vraag stellen maar ik vrees dat ze zelf zullen moeten navraag doen bij de duitse beurs om er een concrete prijs erop te plakken.Alvast bedankt.

sheriff Grover 16 juli 2013 08:39

Genmab A/S: Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement

-- Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case

Copenhagen, Denmark; July 15, 2013 - Genmab A/S (OMX: GEN) announced today that the U.S. Court of Appeals for the Federal Circuit has declined the request for re-hearing. The court upheld its judgment in favor of GlaxoSmithKline (GSK) in the patent infringement case involving Arzerra® brought against GSK by Genentech and Biogen Idec.

The lawsuit is now over unless Genentech and Biogen Idec are granted further review by the Supreme Court.

Genentech and Biogen Idec originally filed the lawsuit in 2010 in the U.S. District Court for the Southern District of California claiming that Arzerra infringed U.S. Patent No. 7,682,612 covering methods of treating Chronic Lymphocytic Leukemia (CLL) with CD20 antibodies. GSK denied infringement and claimed the patent was invalid and unenforceable. An initial judgement by the court in favor of GSK in December 2011 was subsequently appealed by Genentech and Biogen Idec. In April 2013 the US court of appeals upheld the original decision by the US district court in favor of GSK. In May 2013, Genentech and Biogen Idec filed a request for re-hearing en banc (i.e. before all judges of the court) of the decision from the US court of appeals stating that it was against court precedent.

Arzerra is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

sheriff Grover 15 augustus 2013 15:42

Genmab Gains as Nordea Praises Profit Outlook: Copenhagen Mover

By Frances Schwartzkopff - Aug 15, 2013 10:31 AM GMT+0200 .
.

Facebook Share
Tweet
LinkedIn
Google +1
0 Comments

Print

QUEUE

Q

..

Genmab A/S (GEN) rose the most in 11 weeks after Nordea Markets said the biopharmaceutical company is moving closer to becoming profitable, repeating a strong recommendation that investors buy the stock.

Genmab surged as much as 7.8 percent, its biggest advance since May 30, and rose 7.5 percent to 183 kroner at 10:28 a.m. in the Danish capital. Trading volume was at 82 percent of the three-month daily average.

“Genmab is well on its way to sustained profitability,” Michael Novod, an analyst at Nordea Markets, said today in a note to investors. “We repeat strong buy with a 272-krone target.”

Genmab said it expects to lose less money this year than previously forecast amid a 10 million-krone ($2 million) increase in revenue and lower operating costs. The stock has been under pressure since Meditor Capital Management said in June it no longer holds any shares in the company.

“We are not concerned about the Meditor sell-out and believe it was over-interpreted by the market,” Novod said. The “25 percent setback gives a new attractive entry point,” he said.

Genmab said yesterday it expects an operating loss from continuing operations of 10 million kroner to 75 million kroner. That compares with a March forecast for a loss of as much as 90 million kroner.

To contact the reporter on this story: Frances Schwartzkopff in Copenhagen at fschwartzko1@bloomberg.net

To contact the editor responsible for this story: Tasneem Brogger at tbrogger@bloomberg.net Christian Wienberg at cwienberg@bloomberg.net

sheriff Grover 10 september 2013 12:04

Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma

PDF PDF

Company Announcement
•After initial data read-out in Part 1, study may possibly be expanded and continued in Part 2 for use as a potential registration study
•Patient recruitment expected to start soon

Copenhagen, Denmark; September 10, 2013 — Genmab A/S (OMX: GEN) announced today that its partner, Janssen Biotech, Inc. ("Janssen") will start a new Phase II study of daratumumab in multiple myeloma. The Phase II study is designed in 2 parts in multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD. This is the same indication for which daratumumab was granted Breakthrough Therapy Designation from the FDA in May 2013.

"We continue to be excited by the prospects for daratumumab, which has the potential to offer a significant therapeutic alternative for multiple myeloma patients who desperately seek new treatment options," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We look forward to the initiation of this trial with daratumumab in multiple myeloma patients, and we believe this study has the potential to be used for registration in the United States."

About the Study
This two-part study will enroll up to a maximum of 110 patients who have received at least three prior lines of therapy, including both a proteasome inhibitor and an IMiD or who are double refractory to a proteasome inhibitor and an IMiD. Examples of proteasome inhibitors are bortezomib or carfilzomib and examples of IMiD agents are pomalidomide or lenalidomide. Part 1 will define an optimal daratumumab regimen going forward, while part 2 is an expansion based on the optimal regimen determined in Part 1. The primary objective of the study is to define the optimal dose and dosing schedule, to determine the efficacy of two treatment regimens of daratumumab as measured by overall response rate, and to further characterize the safety of daratumumab as a single agent.

About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab could also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma. Daratumumab has been granted Breakthrough Therapy Designation from the US FDA. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop and commercialize daratumumab.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

sheriff Grover 14 september 2013 08:25

Nieuws !!

FDA Grants GSK and Genmab's Arzerra® (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia

PDF PDF

Company Announcement
•Ofatumumab receives Breakthrough Therapy designation in CLL
•Potential for expedited development

Copenhagen, Denmark; September 13, 2013 — Genmab A/S (OMX: GEN) and GlaxoSmithKline plc (GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Arzerra® (ofatumumab) in combination with chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for fludarabine-based therapy. Ofatumumab is not approved or licensed anywhere in the world for use in this treatment setting. Breakthrough Therapy designation is the newest of the FDA's programs aimed at accelerating the development and review times of drugs for serious or life-threatening conditions.

CLL is the most common form of leukemia in adults. Based on estimates by the American Cancer Society, CLL will account for more than 15,680 new cases and more than 4,580 deaths in the United States of America alone in 2013. At present, no curative chemotherapy is available.

The Breakthrough Therapy designation was based on the results from an international, multicenter, randomized Phase III clinical trial in more than 400 patients with previously untreated CLL. Headline results from this trial were announced in May 2013 and the full study results have been submitted for presentation at the 2013 American Society of Hematology Annual Meeting in December.

"We are exceedingly proud to receive the Breakthrough Therapy designation, the second this year for GSK. This FDA program is intended to expedite not just the development but also the review of drugs for serious or life threatening conditions," said Dr. Kathy Rouan, Vice President and Head of Biopharmaceutical Development, GlaxoSmithKline. "We are actively working on our submission and look forward to the enhanced regulatory interaction allowed for Breakthrough Therapies."

"Both of Genmab's lead products, ofatumumab and daratumumab, have now been granted Breakthrough Therapy designations from the FDA. This designation for ofatumumab reflects Genmab's mission to create differentiated products aimed at improving the lives of patients suffering from debilitating diseases and for whom existing treatments are inadequate," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About Breakthrough Therapy designation
The Breakthrough Therapy designation was enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA) and is intended to expedite development and review of drugs to treat serious or life-threatening medical conditions when preliminary clinical evidence demonstrates that the drug may have substantial improvement on at least one clinically significant endpoint over available therapies. Breakthrough Therapy designation includes all the features of the Fast Track designation, as well as more intensive guidance from the FDA on a drug's clinical development program.

About ofatumumab
Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops[i]. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GSK. For Full US Prescribing Information for the approved indication, please visit: us.gsk.com/html/medicines/index.html and visit health.gsk.com for the EU SPC for the approved indication.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

About GSK
GSK — one of the world's leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For further information please visit www.gsk.com.

Genmab Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

Dit versnelt de procedures aanzienlijk , erg prettig !

Sheriff Grover

benito c. 14 september 2013 08:42

Weer opnieuw dank voor alle updates.

poolbeer 14 september 2013 09:27

Prettig bericht zo net voor het weekend.
Voor degene die realtime Genmab koers zoeken.
nl.investing.com/equities/genmab
Bij mijn bank (Rabo) Genmab koers 15 min. vertraging.
bedankt Sheriff.

sheriff Grover 14 september 2013 13:35

Benito geen dank en poolbeer dit is ook wel een prettige RT van de website van Genmab ook incl. grafiek ir.genmab.com/stockquote.cfm
Al met al weer goed nieuws .. met een maand of 6-8 weten we precies waar Genmab staat en December a.s de ASH meeting wordt belangrijk

prettig weekend , Sheriff Grover

sheriff Grover 23 september 2013 12:02

Genmab Reaches 2009 High on Challenge to Roche: Copenhagen Mover

Genmab A/S, the Danish developer of cancer drugs, rose to the highest price in more than four years in Copenhagen trading on bets its leukemia treatment will be able to match a competing product from Roche Holding AG.

Genmab rose as much as 2.4 percent to 223.20 kroner, the highest since June 2009. The stock rose to 219.10 kroner at 11:15 a.m. in the Danish capital, with trading volume at 76 percent of the three-month daily average.

Genmab, based in Copenhagen, said Sept. 13 that the U.S. Food and Drug Administration granted breakthrough status for its leukemia treatment Arzerra, allowing the experimental drug to move faster to the market. Thomas Bowers, an analyst at Danske Markets, said today the status bodes well for the product’s ability to compete with Basel, Switzerland-based Roche’s GA101 treatment.

“The perception of Arzerra is now shifting,” Bowers, who’s based in Copenhagen, said by phone. “The view of Arzerra is changing from a product that the market didn’t rate as highly as GA101, to a product rated on the same level or perhaps even higher.”

Genmab is developing Arzerra with London-based GlaxoSmithKline Plc. Genmab shares have gained 19 percent since the Arzerra announcement.

Breakthrough status, which the FDA assigns to medicines that may be superior to existing drugs for life-threatening medical conditions, will bring Arzerra to the market only “a few months” earlier than previously expected, Bowers said.

“But it’s a big thumbs up from the FDA and sparks optimism about the competitiveness of the product once it hits the market,” said the analyst, who has a buy recommendation on Genmab shares.

To contact the reporter on this story: Christian Wienberg in Copenhagen at cwienberg@bloomberg.net

www.bloomberg.com/news//2013-09-23/ge...

[verwijderd] 19 oktober 2013 18:49

Weekend overdenking over een aandeel in de luwte. Stilletjes is Genmab bezig met flinke opmars. Wat zullen de volgende triggers voor groei zijn? MS is nu ook target ziekte, naast enkele veelbelovende kanker treatments. In dit kader wordt Genmab weer een doel voor enkele van de grote pharmabedrijven met focus op groei door acquisitie. Waarbij sommige van de bestaande ontwikkelpartners c.q. aandeelhouders de meest voor de hand liggende kandidaten zijn.

[verwijderd] 21 oktober 2013 17:46

En weer ruim 3% erbij op een dag. Zie ook persbericht van vrijdagjl.

Copenhagen, Denmark; October 18, 2013 — GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
The application is based on results from an international, multi-center, randomized Phase III study of Arzerra in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL. Headline results from this trial were announced in May 2013 and the full study results are scheduled to be presented in two oral presentations at the 2013 American Society of Hematology Annual Meeting in December.

sheriff Grover 21 oktober 2013 18:09

DKR 250 Sterk (daghoogste) gesloten dus met een beetje geluk loopt het morgen ook nog door ; hoop op DuoBody nieuws (word onderhand wel een beetje tijd) deze week...
Woensdag Arzerra (nog niet al te belangrijk)cijfers . So far So good !

Sheriff Grover

sheriff Grover 23 oktober 2013 13:35

Arzerra® Third Quarter 2013 Net Sales Figures

Company Announcement
•Worldwide net sales of Arzerra® in Q3 2013 totaled GBP 17.8 million
•Genmab expects royalty payment of approx. DKK 31 million

Copenhagen, Denmark; October 23, 2013 — Genmab A/S (OMX: GEN) announced today that the Arzerra (ofatumumab) net sales during the third quarter of 2013 were GBP 17.8 million (approximately DKK 155 million). This figure consists of net sales in the US of GBP 13.1 million and in the rest of the world of GBP 4.7 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 31 million.

During the first half of 2013, rest of world sales of Arzerra were impacted by sales related to the supply of Arzerra for clinical trials run by other companies. Sales were not positively impacted by clinical trial material sales during the third quarter.

The conversion from GBP to DKK has been made using the Danish Central Bank average rates for the third quarter of 2013 (GBP 1.00 = DKK 8.7287).

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

10 % minder dan Q 3 2012 .... allemaal niet erg belangrijk maar omdat inmiddels de Japanse markt er ook is bijgekomen toch een beetje teleurstellend als je het mij vraagt ...

sheriff Grover 6 november 2013 20:00

Genmab Announces Financial Results for the First Nine Months of 2013

Genmab Announces Financial Results for the First Nine Months of 2013 PDF

November 6, 2013; Copenhagen, Denmark;
Interim Report the Nine Months Ended September 30, 2013
•Applications to expand Arzerra® (ofatumumab) label submitted in US & EU
•Received Breakthrough Therapy Designation for ofatumumab
•Sales of Arzerra in first nine months increased 23% over prior year
•Improved operating result by DKK 125 million over nine months 2012
•Guidance maintained

"Throughout the year Genmab has consistently delivered on the goals we communicated to the market. We've reported positive data on ofatumumab, started a new study with daratumumab, are set to start the first clinical trial with HuMax-TF-ADC, have filed applications to expand the label and access to ofatumumab, and have delivered positive financial results. We're also proud to be among a select few companies who have received Breakthrough Therapy Designations for two products and believe this accomplishment is reflective of the leading-edge innovation that is at the heart of Genmab," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Nine Months
•Genmab's revenue was DKK 448 million for the first nine months of 2013 compared to DKK 322 million for the corresponding period in 2012. The increase of DKK 126 million or 39% was mainly driven by higher revenue related to our daratumumab and DuoBody collaborations with Janssen as well as to Arzerra royalties.
•Operating expenses were virtually flat at DKK 432 million in the first nine months of 2013, compared to DKK 430 million in the first nine months of 2012.
•Operating income was DKK 16 million in the first nine months of 2013 compared to an operating loss of DKK 109 million in the corresponding period for 2012, an improvement of DKK 125 million, which was primarily driven by increased revenue.
•The net result for discontinued operation amounted to a net income of DKK 42 million in the first nine months of 2013. The net income in 2013 related to the final few months of running costs of the Minnesota manufacturing facility of DKK 10 million prior to its divestiture and a gain on the sale of DKK 52 million. The facility maintenance cost amounted to DKK 31 million in the first nine months of 2012.
•On September 30, 2013, Genmab had a cash position of DKK 1,498 million. This represented a net decrease of DKK 18 million from the beginning of 2013 which related to the ongoing operating activities, partially offset by the proceeds received from the sale of the manufacturing facility and the exercise of warrants in the first nine months of 2013.

Business Progress Third Quarter to Present
•October: GSK reported net sales for Arzerra for the third quarter of 2013 of GBP 17.8 million, resulting in royalty income of DKK 31 million to Genmab.
•October: Genmab and GSK submitted a supplemental Biologics License Application (sBLA) to the US FDA to expand the label of Arzerra to include use of Arzerra in combination with an alkylator-based therapy for the treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
•October: Genmab and GSK submitted an application (a variation to the Marketing Authorization) to broaden the label for Arzerra to include use of Arzerra in combination with an alkylator-based therapy for the treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy to the European Medicines Agency (EMA).
•October: Positive top-line data from a Phase II study of subcutaneous ofatumumab in RRMS was reported. The results showed a clear separation from placebo on the cumulative number of new gadolinium enhancing lesions (active brain lesions) over a period of 12 weeks in patients treated with all doses of ofatumumab compared to patients treated with placebo.
•September: The US FDA granted Breakthrough Therapy designation for Arzerra in combination with chlorambucil for the treatment of patients with CLL who have not received prior treatment and are inappropriate for fludarabine-based therapy.
•September: Announced that Janssen will start a new Phase II study of daratumumab in multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD.
•August: Reached a technical proof-of-concept milestone in the DuoBody collaboration with Janssen, triggering a milestone payment to Genmab of USD 1 million.
•July: Filed an Investigational New Drug application (IND) with the US FDA for HuMax®-TF-ADC in solid tumors.
•July: Announced a Phase III study of ofatumumab, given subcutaneously to treat pemphigus vulgaris (PV) a rare autoimmune disorder of the skin, run by GSK.
•July: In April, the US Court of Appeals for the Federal Circuit upheld the US District Court's judgment in favor of GSK in a patent infringement case involving Arzerra brought against GSK by Genentech and Biogen Idec. A request for a re-hearing was filed by Genentech and Biogen Idec in May and subsequently refused by the US Court of Appeals in July. This decision is now final as Genentech and Biogen Idec have not requested further review by the Supreme Court.

Outlook
Genmab is maintaining the 2013 financial guidance published on August 14, 2013.

Conference Call
Genmab will hold a conference call in English to discuss the results for the first nine months of 2013 today, Wednesday, November 6, at 6.00 pm CET, 5.00 pm GMT or noon EST. The dial in numbers are:

+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555 131 (international participants) and ask for the Genmab conference call

A live and archived webcast of the call and relevant slides will be available at www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

3.464 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 170 171 172 173 174 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	882,63	+12,36	+1,42%	26 apr
AMX	914,42	-2,12	-0,23%	26 apr
ASCX	1.198,74	+7,95	+0,67%	26 apr
BEL 20	3.874,87	+16,93	+0,44%	26 apr
Germany40^	18.177,90	+260,62	+1,45%	26 apr
US30^	38.211,61	0,00	0,00%	26 apr
US500^	5.095,29	0,00	0,00%	26 apr
Nasd100^	17.698,09	0,00	0,00%	26 apr
Japan225^	38.345,55	0,00	0,00%	26 apr
WTI	83,64	0,00	0,00%	26 apr
Brent	87,99	0,00	0,00%	26 apr
EUR/USD	1,0693	-0,0036	-0,34%	27 apr
BTC/USD	63.101,97	-877,90	-1,37%	27 apr
Gold spot	2.337,95	0,00	0,00%	26 apr